Formylpeptide receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

The formylpeptide receptors (nomenclature agreed by the NC-IUPHAR Subcommittee on the formylpeptide receptor family [185]) respond to exogenous ligands such as the bacterial product fMet-Leu-Phe (fMLP) and endogenous ligands such as annexin I , cathepsin G, amyloid β42, serum amyloid A and spinorphin, derived from β-haemoglobin.

[1]  C. Turck,et al.  Tethered Ligand Library for Discovery of Peptide Agonists (*) , 1995, The Journal of Biological Chemistry.

[2]  J. Unitt,et al.  Discovery of small molecule human FPR1 receptor antagonists. , 2009, Bioorganic & medicinal chemistry letters.

[3]  R. Lefkowitz,et al.  Specific receptor sites for chemotactic peptides on human polymorphonuclear leukocytes. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Khlebnikov,et al.  High-Throughput Screening for Small-Molecule Activators of Neutrophils: Identification of Novel N-Formyl Peptide Receptor Agonists , 2007, Molecular Pharmacology.

[5]  Masaaki Muramatsu,et al.  Polymorphisms of the formylpeptide receptor gene (FPR1) and susceptibility to stomach cancer in 1531 consecutive autopsy cases. , 2011, Biochemical and biophysical research communications.

[6]  C. Serhan,et al.  Resolvin D1 binds human phagocytes with evidence for proresolving receptors , 2010, Proceedings of the National Academy of Sciences.

[7]  A. Gilman,et al.  Inhibition of receptor-mediated release of arachidonic acid by pertussis toxin , 1984, Cell.

[8]  A. Gilman,et al.  G proteins: transducers of receptor-generated signals. , 1987, Annual review of biochemistry.

[9]  M. Perretti,et al.  Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement. , 2006, Blood.

[10]  M. Parmentier,et al.  F2L, a Peptide Derived from Heme-Binding Protein, Chemoattracts Mouse Neutrophils by Specifically Activating Fpr2, the Low-Affinity N-Formylpeptide Receptor1 , 2007, The Journal of Immunology.

[11]  A. Toporik,et al.  A Novel Peptide Agonist of Formyl-Peptide Receptor-Like 1 (ALX) Displays Anti-Inflammatory and Cardioprotective Effects , 2009, Journal of Pharmacology and Experimental Therapeutics.

[12]  H. Shin,et al.  Association analysis of formyl peptide receptor 2 (FPR2) polymorphisms and Aspirin exacerbated respiratory diseases , 2012, Journal of Human Genetics.

[13]  C. Serhan,et al.  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Anti-Inflammatory Actions of Lipoxin A 4 Stable Analogs Are Demonstrable in Human Whole Blood: Modulation of Leukocyte Adhesion Molecules and Inhibition of Neutrophil-Endothelial Interactions , 2016 .

[14]  Marc Parmentier,et al.  Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. , 2006, Cytokine & growth factor reviews.

[15]  C. Serhan,et al.  Lipoxin A4 receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: inhibition of CD11/18 expression by lipoxin A4-lipoxin A4 receptor interaction. , 1995, Biochemistry.

[16]  E. Grazzini,et al.  A truncated form of CKβ8‐1 is a potent agonist for human formyl peptide‐receptor‐like 1 receptor , 2004, British journal of pharmacology.

[17]  R. Ye,et al.  Normal Cell Surface Expression and Selective Loss of Functions Resulting from Phe110 to Ser and Cys126 to Trp Substitutions in the Formyl Peptide Receptor , 2004, Immunological investigations.

[18]  R. Liskamp,et al.  N-Terminal Residues of the Chemotaxis Inhibitory Protein of Staphylococcus aureus Are Essential for Blocking Formylated Peptide Receptor but Not C5a Receptor , 2004, The Journal of Immunology.

[19]  J. Wang,et al.  Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors , 2000, Inflammation Research.

[20]  Jian Huang,et al.  Cutting Edge: A Critical Role for the G Protein-Coupled Receptor mFPR2 in Airway Inflammation and Immune Responses , 2010, The Journal of Immunology.

[21]  Y. Yamamoto,et al.  Inhibitory effects of spinorphin, a novel endogenous regulator, on chemotaxis, O2- generation, and exocytosis by N-formylmethionyl-leucyl-phenylalanine (FMLP)-stimulated neutrophils. , 1997, Biochemical pharmacology.

[22]  M. Perretti,et al.  Stimulus-dependent specificity for annexin 1 inhibition of the inflammatory nociceptive response: the involvement of the receptor for formylated peptides , 2004, Pain.

[23]  P. Murphy,et al.  Amyloid-β Induces Chemotaxis and Oxidant Stress by Acting at Formylpeptide Receptor 2, a G Protein-coupled Receptor Expressed in Phagocytes and Brain* , 2001, The Journal of Biological Chemistry.

[24]  R. Ye,et al.  Pharmacological Characterization of a Novel Nonpeptide Antagonist for Formyl Peptide Receptor-Like 1 , 2007, Molecular Pharmacology.

[25]  R. Ye,et al.  Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. , 2003, Blood.

[26]  W. Gong,et al.  T21/DP107, A synthetic leucine zipper-like domain of the HIV-1 envelope gp41, attracts and activates human phagocytes by using G-protein-coupled formyl peptide receptors. , 1999, Journal of immunology.

[27]  R. Eddy,et al.  Mapping of genes for the human C5a receptor (C5AR), human FMLP receptor (FPR), and two FMLP receptor homologue orphan receptors (FPRH1, FPRH2) to chromosome 19. , 1992, Genomics.

[28]  W. Gong,et al.  Synthetic peptide MMK‐1 is a highly specific chemotactic agonist for leukocyte FPRL1 , 2001, Journal of leukocyte biology.

[29]  E. Prossnitz,et al.  Isolation of a cDNA that encodes a novel granulocyte N-formyl peptide receptor. , 1992, Biochemical and biophysical research communications.

[30]  C. Wennerås,et al.  Cyclosporin H, Boc-MLF and Boc-FLFLF are Antagonists that Preferentially Inhibit Activity Triggered Through the Formyl Peptide Receptor , 2007, Inflammation.

[31]  P. Ward,et al.  The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli. , 1975, Journal of immunology.

[32]  N. Lehman,et al.  Phagocyte cell migration is mediated by phospholipases PLD1 and PLD2. , 2006, Blood.

[33]  Guixiu Shi,et al.  CD38: an ecto-enzyme at the crossroads of innate and adaptive immune responses. , 2007, Advances in experimental medicine and biology.

[34]  M. Parmentier,et al.  Identification and characterization of an endogenous chemotactic ligand specific for FPRL2 , 2005, The Journal of experimental medicine.

[35]  S. Sentellas,et al.  Lack of activity of 15‐epi‐lipoxin A4 on FPR2/ALX and CysLT1 receptors in interleukin‐8‐driven human neutrophil function , 2013, Clinical and experimental immunology.

[36]  M. Jutila,et al.  Molecular docking of 2-(benzimidazol-2-ylthio)-N-phenylacetamide-derived small-molecule agonists of human formyl peptide receptor 1 , 2012, Journal of Molecular Modeling.

[37]  T. Feuerstein,et al.  Differential effects of KATP channel blockers on [3H]-noradrenaline overflow after short- and long-term exposure to (+)-oxaprotiline or desipramine , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[38]  M. Perretti,et al.  Aspirin-triggered 15-epi-lipoxin A4 signals through FPR2/ALX in vascular smooth muscle cells and protects against intimal hyperplasia after carotid ligation , 2015, International journal of cardiology.

[39]  A. Stalder,et al.  Biomarker‐guided clinical development of the first‐in‐class anti‐inflammatory FPR2/ALX agonist ACT‐389949 , 2017, British journal of clinical pharmacology.

[40]  A. Spagnolo,et al.  Lipoxin A4 Counteracts Synergistic Activation of Human Fibroblast-like Synoviocytes , 2004, International journal of immunopathology and pharmacology.

[41]  J. Walters,et al.  Formylpeptide receptor single nucleotide polymorphism 348T>C and its relationship to polymorphonuclear leukocyte chemotaxis in aggressive periodontitis. , 2009, Journal of periodontology.

[42]  T. Takano,et al.  A novel rat lipoxin A4 receptor that is conserved in structure and function , 2003, British journal of pharmacology.

[43]  D. Cockayne,et al.  Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo , 2001, Nature Medicine.

[44]  Y. Bae,et al.  Trp-Arg-Trp-Trp-Trp-Trp antagonizes formyl peptide receptor like 2-mediated signaling. , 2006, Biochemical and biophysical research communications.

[45]  H. Perez,et al.  Signal Transduction by the Formyl Peptide Receptor , 1995, The Journal of Biological Chemistry.

[46]  F. D’Acquisto,et al.  Impaired T cell activation and increased Th2 lineage commitment in Annexin‐1‐deficient T cells , 2007, European journal of immunology.

[47]  P. Janmey,et al.  The two neutrophil members of the formylpeptide receptor family activate the NADPH-oxidase through signals that differ in sensitivity to a gelsolin derived phosphoinositide-binding peptide , 2004, BMC Cell Biology.

[48]  P. Naccache,et al.  Transport of sodium, potassium, and calcium across rabbit polymorphonuclear leukocyte membranes. Effect of chemotactic factor , 1977, The Journal of cell biology.

[49]  Takao Shimizu,et al.  The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo , 2006, Pharmacological Reviews.

[50]  W. Gong,et al.  Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[51]  C. Serhan,et al.  Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. , 2012, The American journal of pathology.

[52]  K. Wenzel-Seifert,et al.  Differential inhibition of human neutrophil activation by cyclosporins A, D, and H. Cyclosporin H is a potent and effective inhibitor of formyl peptide-induced superoxide formation. , 1991, Journal of immunology.

[53]  A. Kirk,et al.  Human platelets exhibit chemotaxis using functional N-formyl peptide receptors. , 2005, Experimental hematology.

[54]  A. Schottelius,et al.  Novel 3-oxa lipoxin A4 analogues with enhanced chemical and metabolic stability have anti-inflammatory activity in vivo. , 2004, Journal of medicinal chemistry.

[55]  C. Serhan,et al.  Aspirin‐triggered lipoxin A4 and lipoxin A4 up‐regulate transcriptional corepressor NAB1 in human neutrophils , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[56]  Tudor I. Oprea,et al.  High-Throughput Screening with HyperCyt® Flow Cytometry to Detect Small Molecule Formylpeptide Receptor Ligands , 2005, Journal of biomolecular screening.

[57]  W. Gong,et al.  Humanin, a Newly Identified Neuroprotective Factor, Uses the G Protein-Coupled Formylpeptide Receptor-Like-1 as a Functional Receptor1 , 2004, The Journal of Immunology.

[58]  C. Dahlgren,et al.  Structural Characterization and Inhibitory Profile of Formyl Peptide Receptor 2 Selective Peptides Descending from a PIP2-Binding Domain of Gelsolin , 2012, The Journal of Immunology.

[59]  A. Fischman,et al.  Selective inhibition of N-formylpeptide-induced neutrophil activation by carbamate-modified peptide analogues. , 1996, Biochemistry.

[60]  P. Smiley,et al.  Association of the N-formyl-Met-Leu-Phe receptor in human neutrophils with a GTP-binding protein sensitive to pertussis toxin. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[61]  J. Werba,et al.  Transcriptional regulation of the human FPR2/ALX gene: evidence of a heritable genetic variant that impairs promoter activity , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[62]  W. Gong,et al.  T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor. , 1999, Blood.

[63]  T. Takano,et al.  Lipoxin A4 Stable Analogs Are Potent Mimetics That Stimulate Human Monocytes and THP-1 Cells via a G-protein-linked Lipoxin A4 Receptor* , 1997, The Journal of Biological Chemistry.

[64]  M. Perretti,et al.  A vasculo-protective circuit centered on lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 operative in murine microcirculation. , 2013, Blood.

[65]  K. Wenzel-Seifert,et al.  Cyclosporin H is a potent and selective formyl peptide receptor antagonist. Comparison with N-t-butoxycarbonyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L- leucyl-L-phenylalanine and cyclosporins A, B, C, D, and E. , 1993, Journal of immunology.

[66]  K. Wenzel-Seifert,et al.  Cyclosporin H Is a Potent and Selective Formyl Peptide Receptor Antagonist Comparison with Nt-Butoxycarbonyl-~-phenylalanyl-L-leucyl-L-phenylalanyl-1-leucyl-L-phenylalanine and Cyclosporins , 2001 .

[67]  M. Hersberger,et al.  No evidence for the involvement of the lipoxin A4 receptor (FPR2/ALX) gene in the susceptibility to coronary artery disease , 2012, Clinical chemistry and laboratory medicine.

[68]  R. Ye,et al.  Human dendritic cells express functional formyl peptide receptor‐like‐2 (FPRL2) throughout maturation , 2002, Journal of leukocyte biology.

[69]  J. Varga,et al.  Opposing Regulation of Interleukin-8 and NF-kB Responses by Lipoxin A4 and Serum Amyloid a via the Common Lipoxin a Receptor , 2004, International journal of immunopathology and pharmacology.

[70]  J. Kwak,et al.  Identification of Peptides That Antagonize Formyl Peptide Receptor-Like 1-Mediated Signaling1 , 2004, The Journal of Immunology.

[71]  R. Egan,et al.  Phosphatidylcholine hydrolysis by phospholipase D determines phosphatidate and diglyceride levels in chemotactic peptide-stimulated human neutrophils. Involvement of phosphatidate phosphohydrolase in signal transduction. , 1989, The Journal of biological chemistry.

[72]  K. Wenzel-Seifert,et al.  Defective Gi Protein Coupling in Two Formyl Peptide Receptor Mutants Associated with Localized Juvenile Periodontitis* , 2001, The Journal of Biological Chemistry.

[73]  P. Murphy,et al.  The Endogenous Opioid Spinorphin Blocks fMet-Leu-Phe-Induced Neutrophil Chemotaxis by Acting as a Specific Antagonist at the N-Formylpeptide Receptor Subtype FPR , 2001, The Journal of Immunology.

[74]  R. Hannon,et al.  Anti-Inflammatory Role of the Murine Formyl-Peptide Receptor 2: Ligand-Specific Effects on Leukocyte Responses and Experimental Inflammation , 2010, The Journal of Immunology.

[75]  S. Lockett,et al.  Identification of Neutrophil Granule Protein Cathepsin G as a Novel Chemotactic Agonist for the G Protein-Coupled Formyl Peptide Receptor 12 , 2004, The Journal of Immunology.

[76]  G. Bartolucci,et al.  Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists. , 2012, Bioorganic & medicinal chemistry.

[77]  A. Young,et al.  Lipoxin A4 Analogs Attenuate Induction of Intestinal Epithelial Proinflammatory Gene Expression and Reduce the Severity of Dextran Sodium Sulfate-Induced Colitis1 , 2002, The Journal of Immunology.

[78]  T. Takenawa,et al.  Role of enhanced inositol phospholipid metabolism in neutrophil activation. , 1985, Biochemical pharmacology.

[79]  Anna Karlsson,et al.  A Proinflammatory Peptide from Herpes Simplex Virus Type 2 Glycoprotein G Affects Neutrophil, Monocyte, and NK Cell Functions1 , 2005, The Journal of Immunology.

[80]  Ji Ming Wang,et al.  The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[81]  J. Broach,et al.  Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast , 1998, Nature Biotechnology.

[82]  S. Visvikis-Siest,et al.  Human formyl peptide receptor 1 C32T SNP interacts with age and is associated with blood pressure levels. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[83]  J. McClary,et al.  Cloning of a cDNA encoding a receptor related to the formyl peptide receptor of human neutrophils. , 1992, Gene.

[84]  P A Ward,et al.  Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. , 1984, The Journal of biological chemistry.

[85]  C B Wollheim,et al.  Is cytosolic ionized calcium regulating neutrophil activation? , 1983, Science.

[86]  P. Henson,et al.  The sequential release of granule constitutents from human neutrophils. , 1980, Journal of immunology.

[87]  Ji Ming Wang,et al.  Ll-37, the Neutrophil Granule–And Epithelial Cell–Derived Cathelicidin, Utilizes Formyl Peptide Receptor–Like 1 (Fprl1) as a Receptor to Chemoattract Human Peripheral Blood Neutrophils, Monocytes, and T Cells , 2000, The Journal of experimental medicine.

[88]  M. Perretti,et al.  Glucocorticoid upregulation of the annexin-A1 receptor in leukocytes. , 2006, Biochemical and biophysical research communications.

[89]  S. Hinuma,et al.  N-Formylated humanin activates both formyl peptide receptor-like 1 and 2. , 2004, Biochemical and biophysical research communications.

[90]  L. Mcphail,et al.  Measurement of phospholipid metabolism in intact neutrophils. , 2007, Methods in molecular biology.

[91]  J. Woska,et al.  Broad immunocytochemical localization of the formylpeptide receptor in human organs, tissues, and cells , 1998, Cell and Tissue Research.

[92]  E. Prossnitz,et al.  Multiple domains of the N-formyl peptide receptor are required for high-affinity ligand binding. Construction and analysis of chimeric N-formyl peptide receptors. , 1993, The Journal of biological chemistry.

[93]  L. Pardo,et al.  Structural Determinants for the Interaction of Formyl Peptide Receptor 2 with Peptide Ligands* , 2013, The Journal of Biological Chemistry.

[94]  J. Kwak,et al.  Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. , 2005, Biochemical and biophysical research communications.

[95]  M. Perretti,et al.  Ligand-specific conformational change of the G-protein–coupled receptor ALX/FPR2 determines proresolving functional responses , 2013, Proceedings of the National Academy of Sciences.

[96]  Tudor I. Oprea,et al.  A non-peptide receptor inhibitor with selectivity for one of the neutrophil formyl peptide receptors, FPR 1. , 2012, Biochemical pharmacology.

[97]  G. Downey,et al.  Involvement of Cytosolic Phospholipase A2 and Secretory Phospholipase A2 in Arachidonic Acid Release from Human Neutrophils1 , 2000, The Journal of Immunology.

[98]  C. Dahlgren,et al.  Lipoxin A4 Metabolites/Analogues from Two Commercial Sources have No Effects on TNF‐α‐mediated Priming or Activation through the Neutrophil Formyl Peptide Receptors , 2009, Scandinavian journal of immunology.

[99]  Shuguang Zhang,et al.  Production of a Bioengineered G-Protein Coupled Receptor of Human Formyl Peptide Receptor 3 , 2011, PloS one.

[100]  P. Murphy,et al.  Impaired Antibacterial Host Defense in Mice Lacking the N-formylpeptide Receptor , 1999, The Journal of experimental medicine.

[101]  D. Haviland,et al.  N-formylpeptide and complement C5a receptors are expressed in liver cells and mediate hepatic acute phase gene regulation , 1995, The Journal of experimental medicine.

[102]  S. Marullo,et al.  Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor , 2002, Nature Medicine.

[103]  Jennifer E. Golden,et al.  Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. , 2006, Bioorganic & medicinal chemistry letters.

[104]  R. Ye,et al.  Functional Characterization of Three Mouse Formyl Peptide Receptors , 2013, Molecular Pharmacology.

[105]  D. McDermott,et al.  Contrasting evolution of the human leukocyte N-formylpeptide receptor subtypes FPR and FPRL1R , 2001, Genes and Immunity.

[106]  W. Gong,et al.  Silencing the Formylpeptide Receptor FPR by Short-Interfering RNA , 2004, Molecular Pharmacology.

[107]  Ronald Anderson,et al.  Activation of Human Neutrophils with Chemotactic Peptide, Opsonized Zymosan and the Calcium Ionophore A23187, But Not with a Phorbol Ester, is Accompanied by Efflux and Store-Operated Influx of Calcium , 2000, Inflammation.

[108]  M. Jutila,et al.  Identification of Novel Small-Molecule Agonists for Human Formyl Peptide Receptors and Pharmacophore Models of Their Recognition , 2010, Molecular Pharmacology.

[109]  C. Kozak,et al.  Differential expansion of the N-formylpeptide receptor gene cluster in human and mouse. , 1998, Genomics.

[110]  C. Serhan,et al.  Induction of functional lipoxin A4 receptors in HL-60 cells. , 1993, Blood.

[111]  C. Serhan,et al.  Lipoxin recognition sites. Specific binding of labeled lipoxin A4 with human neutrophils. , 1992, The Journal of biological chemistry.

[112]  W. Junger,et al.  Circulating Mitochondrial DAMPs Cause Inflammatory Responses to Injury , 2009, Nature.

[113]  A. Jesaitis,et al.  Reconstitution of recombinant N‐formyl chemotactic peptide receptor with G protein , 1993, Journal of leukocyte biology.

[114]  K. Hellstrand,et al.  A proinflammatory peptide from Helicobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosis. , 2001, The Journal of clinical investigation.

[115]  C. Movitz,et al.  Neutrophil NADPH‐oxidase activation by an annexin AI peptide is transduced by the formyl peptide receptor (FPR), whereas an inhibitory signal is generated independently of the FPR family receptors , 2005, Journal of leukocyte biology.

[116]  W. Gong,et al.  Activation of the chemotactic peptide receptor FPRL1 in monocytes phosphorylates the chemokine receptor CCR5 and attenuates cell responses to selected chemokines. , 2000, Biochemical and biophysical research communications.

[117]  U. Rescher,et al.  An Annexin 1 N-Terminal Peptide Activates Leukocytes by Triggering Different Members of the Formyl Peptide Receptor Family1 , 2004, The Journal of Immunology.

[118]  T. Schöneberg,et al.  Human formyl peptide receptor 2 senses highly pathogenic Staphylococcus aureus. , 2010, Cell host & microbe.

[119]  M. Tardif,et al.  Synthesis and use of a novel N-formyl peptide derivative to isolate a human N-formyl peptide receptor cDNA. , 1990, Biochemical and biophysical research communications.

[120]  B. Engelhardt,et al.  Ligand-induced adhesion to activated endothelium and to vascular cell adhesion molecule-1 in lymphocytes transfected with the N-formyl peptide receptor. , 1994, Journal of immunology.

[121]  R. Egan,et al.  Phospholipase D catalyzes phospholipid metabolism in chemotactic peptide-stimulated HL-60 granulocytes. , 1988, The Journal of biological chemistry.

[122]  Hae‐Sim Park,et al.  The genetic association of the FPRL1 promoter polymorphism with chronic urticaria in a Korean population. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[123]  C. Mackay,et al.  Biology of chemokine and classical chemoattractant receptors: differential requirements for adhesion-triggering versus chemotactic responses in lymphoid cells , 1996, The Journal of cell biology.

[124]  R. Lefkowitz,et al.  The oligopeptide chemotactic factor receptor on human polymorphonuclear leukocyte membranes exists in two affinity states. , 1982, Biochemical and biophysical research communications.

[125]  S. Whittemore,et al.  Expression of the receptors for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia , 1995, Journal of Neuroimmunology.

[126]  B. Premack,et al.  Proinflammatory Proteases Liberate a Discrete High-Affinity Functional FPRL1 (CCR12) Ligand from CCL2312 , 2007, The Journal of Immunology.

[127]  T. Usdin,et al.  Reduced Fear Memory and Anxiety-like Behavior in Mice Lacking Formylpeptide Receptor 1 , 2011, Behavior genetics.

[128]  U. Francke,et al.  A structural homologue of the N-formyl peptide receptor. Characterization and chromosome mapping of a peptide chemoattractant receptor family. , 1992, The Journal of biological chemistry.

[129]  R. Ye,et al.  The Immunosuppressant Cyclosporin A Antagonizes Human Formyl Peptide Receptor through Inhibition of Cognate Ligand Binding1 , 2006, The Journal of Immunology.

[130]  Hugh R. Brady,et al.  Cutting Edge: Lipoxins Rapidly Stimulate Nonphlogistic Phagocytosis of Apoptotic Neutrophils by Monocyte-Derived Macrophages1 , 2000, The Journal of Immunology.

[131]  M. Perretti,et al.  Resolvin D1 Limits Polymorphonuclear Leukocyte Recruitment to Inflammatory Loci: Receptor-Dependent Actions , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[132]  W. Gong,et al.  Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation. , 1999, Journal of immunology.

[133]  M. Wenlock,et al.  Lead optimisation of pyrazoles as novel FPR1 antagonists. , 2012, Bioorganic & medicinal chemistry letters.

[134]  F. Yarovinsky,et al.  Mouse Cathelin-Related Antimicrobial Peptide Chemoattracts Leukocytes Using Formyl Peptide Receptor-Like 1/Mouse Formyl Peptide Receptor-Like 2 as the Receptor and Acts as an Immune Adjuvant1 , 2005, The Journal of Immunology.

[135]  R. Ye,et al.  Identification of Formyl Peptides from Listeria monocytogenes and Staphylococcus aureus as Potent Chemoattractants for Mouse Neutrophils1 , 2008, The Journal of Immunology.

[136]  C. Serhan,et al.  Aspirin-Triggered Lipoxin A4 and B4 Analogs Block Extracellular Signal-Regulated Kinase-Dependent TNF-α Secretion from Human T Cells 1 , 2003, The Journal of Immunology.

[137]  K. Krause,et al.  Chemotactic peptide activation of human neutrophils and HL-60 cells. Pertussis toxin reveals correlation between inositol trisphosphate generation, calcium ion transients, and cellular activation. , 1985, The Journal of clinical investigation.

[138]  W. Gong,et al.  Formylpeptide receptor-2 contributes to colonic epithelial homeostasis, inflammation, and tumorigenesis. , 2013, The Journal of clinical investigation.

[139]  S. Ryu,et al.  A peptide with unique receptor specificity: stimulation of phosphoinositide hydrolysis and induction of superoxide generation in human neutrophils. , 1997, Journal of immunology.

[140]  M. Tardif,et al.  The human N-formylpeptide receptor. Characterization of two cDNA isolates and evidence for a new subfamily of G-protein-coupled receptors. , 1990, Biochemistry.

[141]  A. Jesaitis,et al.  Chemotaxis of chinese hamster ovary cells expressing the human neutrophil formyl peptide receptor: role of signal transduction molecules and alpha5beta1 integrin. , 1998, Journal of cell science.

[142]  C. Serhan,et al.  Activation of Lipoxin a4 Receptors by Aspirin-Triggered Lipoxins and Select Peptides Evokes Ligand-Specific Responses in Inflammation , 2000, The Journal of experimental medicine.

[143]  M. Billah,et al.  Phospholipase C and phospholipase D are activated independently of each other in chemotactic peptide‐stimulated human neutrophils , 1993, Journal of leukocyte biology.

[144]  C. Serhan,et al.  Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[145]  Huiping Jiang,et al.  Pertussis Toxin-sensitive Activation of Phospholipase C by the C5a and fMet-Leu-Phe Receptors* , 1996, The Journal of Biological Chemistry.

[146]  I. Williams,et al.  Lateral membrane LXA4 receptors mediate LXA4's anti-inflammatory actions on intestinal epithelium. , 2003, American journal of physiology. Cell physiology.

[147]  C. Serhan,et al.  Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor , 1994, The Journal of experimental medicine.

[148]  A. Sharma,et al.  Single nucleotide polymorphisms of the N-formyl peptide receptor in localized juvenile periodontitis. , 1999, Journal of periodontology.

[149]  M. Perretti,et al.  Involvement of the receptor for formylated peptides in the in vivo anti-migratory actions of annexin 1 and its mimetics. , 2001, The American journal of pathology.

[150]  E. Leonard,et al.  A series of six ligands for the human formyl peptide receptor: tetrapeptides with high chemotactic potency and efficacy. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[151]  P. Cuatrecasas,et al.  Receptor-mediated internalization of fluorescent chemotactic peptide by human neutrophils. , 1979, Science.

[152]  R. Ammendola,et al.  Distinct Signaling Cascades Elicited by Different Formyl Peptide Receptor 2 (FPR2) Agonists , 2013, International journal of molecular sciences.

[153]  Marc Parmentier,et al.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the Formyl Peptide Receptor (FPR) Family , 2009, Pharmacological Reviews.

[154]  P. Murphy,et al.  The HIV-1 cell entry inhibitor T-20 potently chemoattracts neutrophils by specifically activating the N-formylpeptide receptor. , 2000, Biochemical and biophysical research communications.

[155]  F. Boulay,et al.  Human mitochondria‐derived N‐formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes‐derived peptides preferentially activate FPR , 2005, European journal of immunology.

[156]  Philip M Murphy,et al.  Formyl-peptide receptors revisited. , 2002, Trends in immunology.

[157]  W. Gong,et al.  Expression of functional formyl peptide receptors by human astrocytoma cell lines , 2000, Journal of Neuroimmunology.

[158]  N. Ferreirós,et al.  Heterologously expressed formyl peptide receptor 2 (FPR2/ALX) does not respond to lipoxin A₄. , 2013, Biochemical pharmacology.

[159]  W. Gong,et al.  Formylpeptide receptors are critical for rapid neutrophil mobilization in host defense against Listeria monocytogenes , 2012, Scientific Reports.

[160]  C. Dahlgren,et al.  The Synthetic Peptide Trp-Lys-Tyr-Met-Val-Met-NH2 Specifically Activates Neutrophils through FPRL1/Lipoxin A4 Receptors and Is an Agonist for the Orphan Monocyte-expressed Chemoattractant Receptor FPRL2* , 2001, The Journal of Biological Chemistry.

[161]  F Sherman,et al.  Methionine or not methionine at the beginning of a protein , 1985, BioEssays : news and reviews in molecular, cellular and developmental biology.

[162]  G. Barish,et al.  N-Formylpeptides Induce Two Distinct Concentration Optima for Mouse Neutrophil Chemotaxis by Differential Interaction with Two N-Formylpeptide Receptor (Fpr) Subtypes , 1999, The Journal of experimental medicine.

[163]  Clemencia Pinilla,et al.  Selective Agonists and Antagonists of Formylpeptide Receptors: Duplex Flow Cytometry and Mixture-Based Positional Scanning Libraries , 2013, Molecular Pharmacology.

[164]  J. Walters,et al.  Neutrophil formylpeptide receptor single nucleotide polymorphism 348T>C in aggressive periodontitis. , 2009, Journal of periodontology.

[165]  T. Takano,et al.  Aspirin-triggered 15-Epi-Lipoxin A4 (LXA4) and LXA4 Stable Analogues Are Potent Inhibitors of Acute Inflammation: Evidence for Anti-inflammatory Receptors , 1997, The Journal of experimental medicine.

[166]  B. Levy,et al.  Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: a ‘stop’ signaling switch for aspirin‐triggered lipoxin A4 , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[167]  R. D. Mellon,et al.  Regulatory effects of deoxycholic acid, a component of the anti-inflammatory traditional Chinese medicine Niuhuang, on human leukocyte response to chemoattractants. , 2002, Biochemical pharmacology.

[168]  Zigmond Sh.  Ability of polymorphonuclear leukocytes to orient in gradients of chemotactic factors. , 1977 .

[169]  V. Gerke,et al.  A novel ligand of the formyl peptide receptor: annexin I regulates neutrophil extravasation by interacting with the FPR. , 2000, Molecular cell.

[170]  A. Jesaitis,et al.  399 MUTATIONS OF F110 AND C126 OF THE FORMYL PEPTIDE RECEPTOR INTERFERE WITH G-PROTEIN COUPLING AND CHEMOTAXIS. , 2003, Journal of Investigative Medicine.

[171]  A. Day,et al.  Formyl peptide chemoattractants: a model of the receptor on rabbit neutrophils. , 1982, Biochemistry.

[172]  Ji Ming Wang,et al.  Peptide Receptor Chemotactic Agonist for Mouse Formyl Trp-Lys-Tyr-Met-Val-d-Met Is a Potent The Synthetic Peptide and , 2000 .

[173]  H. Carp.  Mitochondrial N-formylmethionyl proteins as chemoattractants for neutrophils , 1982, The Journal of experimental medicine.

[174]  Tudor I. Oprea,et al.  Discovery of selective probes and antagonists for G-protein-coupled receptors FPR/FPRL1 and GPR30. , 2009, Current topics in medicinal chemistry.

[175]  C. Clish,et al.  Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo , 1999 .

[176]  J. Varga,et al.  Lipoxin A4 Inhibits IL-1β-Induced IL-6, IL-8, and Matrix Metalloproteinase-3 Production in Human Synovial Fibroblasts and Enhances Synthesis of Tissue Inhibitors of Metalloproteinases1 , 2000, The Journal of Immunology.

[177]  S. Su,et al.  N36, a synthetic N-terminal heptad repeat domain of the HIV-1 envelope protein gp41, is an activator of human phagocytes. , 2000, Clinical immunology.

[178]  C. Dahlgren,et al.  N-Formyl Peptide Receptor 3 (FPR3) Departs from the Homologous FPR2/ALX Receptor with Regard to the Major Processes Governing Chemoattractant Receptor Regulation, Expression at the Cell Surface, and Phosphorylation , 2011, The Journal of Biological Chemistry.

[179]  C. Serhan,et al.  Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. , 2001, The American journal of pathology.

[180]  J. V. van Strijp,et al.  A New Staphylococcal Anti-Inflammatory Protein That Antagonizes the Formyl Peptide Receptor-Like 11 , 2006, The Journal of Immunology.

[181]  P. Kubes,et al.  Intravascular Danger Signals Guide Neutrophils to Sites of Sterile Inflammation , 2010, Science.

[182]  J. A. Radding,et al.  Further studies on the structural requirements for synthetic peptide chemoattractants. , 1980, Biochemistry.

[183]  C. Serhan,et al.  Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction , 1996, The Journal of experimental medicine.

[184]  R. Ye,et al.  A Novel Nonpeptide Ligand for Formyl Peptide Receptor-Like 1 , 2004, Molecular Pharmacology.

[185]  Tudor I. Oprea,et al.  Integration of Virtual Screening with High-Throughput Flow Cytometry to Identify Novel Small Molecule Formylpeptide Receptor Antagonistss⃞ , 2005, Molecular Pharmacology.

[186]  A. Narang,et al.  Immunostaining evidence for PI(4,5)P2 localization at the leading edge of chemoattractant‐stimulated HL‐60 cells , 2008, Journal of leukocyte biology.

[187]  S. Zigmond,et al.  The structure-activity relations of synthetic peptides as chemotactic factors and inducers of lysosomal secretion for neutrophils , 1976, The Journal of experimental medicine.

[188]  S. Wahl,et al.  N-formylmethionyl peptides as chemoattractants for leucocytes. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[189]  M. Perretti,et al.  Leukocyte antiadhesive actions of annexin 1: ALXR- and FPR-related anti-inflammatory mechanisms. , 2003, Blood.

[190]  W. Gong,et al.  A Seven-transmembrane, G Protein–coupled Receptor, FPRL1, Mediates the Chemotactic Activity of Serum Amyloid A for Human Phagocytic Cells , 1999, The Journal of experimental medicine.

[191]  W. Gong,et al.  A synthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R. , 1999, Blood.